Skip to main content

Chicken anti-Human IgG (H+L) Secondary Antibody

Novus Biologicals, part of Bio-Techne | Catalog # NB120-6713

Catalog #
Availability
Size / Price
Qty
Loading...
NB120-6713

Key Product Details

Species Reactivity

Human

Applications

Dot Blot, ELISA, Immunohistochemistry, Western Blot

Label

Unconjugated

Antibody Source

Polyclonal Chicken IgG

Concentration

Please see the vial label for concentration. If unlisted please contact technical services.

Product Specifications

Immunogen

Human IgG whole molecule

Clonality

Polyclonal

Host

Chicken

Isotype

IgG

Description

This product was prepared from monospecific antiserum by immunoaffinity chromatography using Human IgG coupled to agarose beads followed by solid phase adsorption(s) to remove any unwanted reactivities. Assay by immunoelectrophoresis resulted in a single precipitin arc against anti-Chicken Serum, Human IgG and Human Serum.

Store vial at 4C prior to opening. This product is stable for several weeks at 4C as an undiluted liquid. Dilute only prior to immediate use. For extended storage aliquot contents and freeze at -20C or below. Avoid cycles of freezing and thawing.

Scientific Data Images for Chicken anti-Human IgG (H+L) Secondary Antibody

Western Blot: Chicken anti-Human IgG (H+L) Secondary Antibody [NB120-6713]

Western Blot: Chicken anti-Human IgG (H+L) Secondary Antibody [NB120-6713]

Western Blot: Chicken anti-Human IgG (H+L) Secondary Antibody [NB120-6713] - Lane 1: Human IgG. Load: 100 ug per lane. Secondary antibody: Human IgG (H&L) Antibody Peroxidase conjugated at 1:1,000 for 60 min at RT. Blocking buffer for 30 min at RT. Predicted/Observed size: 55 and 28 kDa, 55 and 28 kDa. Image using the HRP format of this antibody.
Western Blot: Chicken anti-Human IgG (H+L) Secondary Antibody [NB120-6713]

Western Blot: Chicken anti-Human IgG (H+L) Secondary Antibody [NB120-6713]

Western Blot: Chicken anti-Human IgG (H+L) Secondary Antibody [NB120-6713] - Lane 1: Human IgG Load: 100 ug per lane Secondary antibody: Human IgG (H&L) Antibody Alkaline Phosphatase conjugated at 1:1,000 for 60 min at RT. Blocking buffer for 30 min at RT Predicted/Observed size: 55 and 28 kDa, 55 kDa. Image using the Alkaline Phosphatase format of this antibody.
Dot Blot: Chicken anti-Human IgG (H+L) Secondary Antibody [NB120-6713] - Dot Blot of Chicken anti-Human IgG (H+L) Secondary Antibody [FITC]. Lane 1: 100ng. Lane 2: 33.3ng. Lane 3: 11.1ng. Lane 4: 3.7ng. Lane 5: 1.23ng. Chicken anti-Human IgG (H+L) Secondary Antibody [FITC] 1ug/ml. Blocked for 30 min at RT. Image from the FITC version of this antibody.

Applications for Chicken anti-Human IgG (H+L) Secondary Antibody

Application
Recommended Usage

ELISA

1:20000 - 1:100000

Immunohistochemistry

1:1000 - 1:5000

Western Blot

1:2000 - 1:10000
Application Notes
This product has been tested by ELISA and is suitable for western blot and immunohistochemistry, as well as other assays requiring lot-to-lot consistency.

Formulation, Preparation, and Storage

Purification

Multi-step

Formulation

0.02 M Potassium Phosphate, 0.15 M Sodium Chloride, pH 7.2

Preservative

0.01% Sodium Azide

Concentration

Please see the vial label for concentration. If unlisted please contact technical services.

Shipping

The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.

Stability & Storage

Store at 4C short term. Aliquot and store at -20C long term. Avoid freeze-thaw cycles.

Background: IgG (H+L)

Antibodies, also known as immunoglobulins (Igs) are critical for immunity and are grouped into five primary classes: IgG, IgM, IgA, IgD, and IgE. The most abundant antibody isotype is immunoglobulin G (IgG) with concentrations ranging from 7.5-22 mg/ml in human serum and has a molecular weight of 150 kDa. The major effector functions of IgG include neutralization, opsonization, complement fixation and antibody dependent cell-mediated cytotoxicity (ADCC). This monomeric immunoglobulin, expressed on the surface of mature B cells, is often depicted as a Y-shape and comprised of 2 heavy chains and 2 light chains linked by disulfide bonds. The heavy chain is type gamma including subtypes gamma 1, gamma 2, gamma 3, and gamma 4 while the light chain is either a kappa or lambda chain. An IgG molecule has two antigen binding sites, each consisting of a heavy and light chain N-terminal variable domain. When combined with the constant heavy chain 1 (Ch1) and the constant light chain domains, it forms the fragment antigen-binding (Fab) region (2 per antibody). The remaining domains (Ch2-Ch4) of both heavy chains make up the Fc region and contain a site for covalently linking an enzymatic or fluorochrome probe, such as HRP or Janelia Fluor 549, for target detection and visualization (1,2,3).

The 4 IgG subclasses, sharing 95% amino acid identity, include IgG1, IgG2, IgG3, and IgG4 for humans and IgG1, IgG2a, IgG2b, and IgG3 for mice. The relative abundance of each human subclass is 60% for IgG1, 32% for IgG2, 4% for IgG3, and 4% for IgG4. In an IgG deficiency, there may be a shortage of one or more subclasses (4).

References

1. Painter RH. (1998) Encyclopedia of Immunology (Second Edition). Elsevier. 1208-1211

2. Chapter 9 - Antibodies. (2012) Immunology for Pharmacy. Mosby 70-78

3. Schroeder H, Cavacini, L. (2010) Structure and Function of Immunoglobulins. J Allergy Clin Immunol. 125(2 0 2): S41-S52. PMID: 20176268

4. Vidarsson G, Dekkers G, Rispens T. (2014) IgG subclasses and allotypes: from structure to effector functions. Front Immunol. 5:520. PMID: 25368619

Additional IgG (H+L) Products

Product Documents for Chicken anti-Human IgG (H+L) Secondary Antibody

Certificate of Analysis

To download a Certificate of Analysis, please enter a lot number in the search box below.

Product Specific Notices for Chicken anti-Human IgG (H+L) Secondary Antibody

Chicken products cannot be exported to Canada.

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Secondary Antibodies are guaranteed for 1 year from date of receipt.

Loading...
Loading...
Loading...
Loading...